Bipolar Disorder - New treatments for bipolar depression set to drive near-term growth

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-09-05

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Stimulated by sales of atypical antipsychotics for bipolar depression, and despite the launch of generic risperidone, the global bipolar disorder market will grow until 2011, when revenues will peak at $6.6 billion. The market will begin to decline thereafter owing to the launch of generic versions of the leading atypical antipsychotics, quetiapine, olanzapine, and ziprasidone from 2011 onwards.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in bipolar disorder
  • Overview of drugs in pre-registration, Phase III, II and I; with analysis of key companies involved in the market
  • Detailed profiles of key compounds in development for use in bipolar disorder, with forecasts of drug revenues to 2015
  • Discussion of indication expansion strategies and insight from key industry opinion leaders


    • Report Highlights
    AstraZeneca will be the first company to bring an atypical antipsychotic to the bipolar depression market as a monotherapy, following demonstration of efficacy with quetiapine. Pfizer will maintain a strong schizophrenia franchise by releasing asenapine to buffer the loss in revenue due to genericization of ziprasidone.

    Solvay/Wyeth/Lundbeck's bifeprunox will be the leading market entrant in terms of bipolar disorder specific sales revenue. These companies appear to be seeking initial license for bifeprunox in the bipolar depression indication, a tactic that will both increase the commercial viability of the drug and save time/money.

    Despite the commercial success of Lamictal (lamotrigine) and Depakote (valproate), the late-stage bipolar disorder pipeline only includes one anticonvulsant class molecule, Novartis' licarbazepine.


    Reasons to Purchase

  • Understand unmet needs in the bipolar disorder market based on key opinion leader comments
  • Benchmark key late-stage bipolar disorder compounds against current market leaders
  • Assess the global (US, Japan, five major EU) sales forecasts of late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: bipolar mania depression antipsychotic antidepressant bipolar memantine depression noncompliance generic effects ziprasidone consta uridine side

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.